US Patent

US11944612 — Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde

Method of Use · Assigned to Global Blood Therapeutics Inc · Expires 2036-12-02 · 11y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating sickle cell disease by administering a specific compound, 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde, in certain dosing regimens.

USPTO Abstract

Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.

Drugs covered by this patent

Oxbryta (voxelotor) · Global Blood Theraps

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3893`	—	Oxbryta
`U-3893`	—	Oxbryta
`U-3893`	—	Oxbryta

Patent Metadata

Patent number: US11944612
Jurisdiction: US
Classification: Method of Use
Expires: 2036-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Global Blood Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.